Antigen

#Antigen #Cancer vaccine #Drug development #Drug discovery #Infinitopes #Society of Immunotherapy for Cancer (SITC)

Breakthroughs on cancer vaccine development at SITC 2024 

Infinitopes presented three posters on its cancer vaccine discovery and development strategy, including one that has been recognised as a ‘top 100’ poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10 November.  A spinout from Oxford University, supported by Cancer Research UK (CRUK),… Read More

#Cancer Research #News

Cancer research in lab
#Antigen #Immunology #Oncology #Prostate cancer #University of California San Francisco

Study reveals insights into antigen reactivity in prostate cancer

Researchers from the University of California, San Francisco (UCSF) shared new data on foundational prostate cancer antigen research at the 2024 Annual Meeting of the American Association of Immunologists (AAI) in Chicago. Prostate cancer’s low mutation burden has resulted in very few druggable neoantigens –… Read More

#Cancer Research #News

#Antigen #Biotechnology #Immunology / Virology & Vaccines #mRNA #RNA #Therapeutics

What’s next for RNA-based medicine post-Covid-19?

Dr Pirkko Muhonen, Senior Field Application Scientist, Nucleic Acid Therapeutics, at Thermo Fisher Scientific, shares what’s next for RNA-based medicine post-pandemic with DDW. With SARS-CoV-2 circulating the globe and leading to over five million deaths worldwide1, all eyes are on the critical role messenger RNA (mRNA) vaccines are playing in… Read More

#Covid-19 #Exclusive Content #News #Trends & Analysis

#Antigen #Biotechnology #Collaboration

Collaboration: discovery against GPCRs, ion channels and transporters 

Swedish biotech company Salipro Biotech has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro Platform, which stabilises challenging G protein coupled receptor (GPCR), ion channel and transporter antigens.  “We are excited to build on the success of our previous studies and deepen our relationship with the team at AbCellera,”… Read More

#News

#Antigen #Awards #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Winners of ‘The Best Covid-19 Responder’ announced

The Native Antigen Company has won ‘The Best Covid-19 Responder’ at the OBN 2020 Awards. The award recognises the Company’s contribution to the fight against Covid-19. The Native Antigen Company has utilised its expertise in developing high-quality reagents to play a major role in the global response to SARS-CoV-2. In… Read More

#News

#Antigen #Drug discovery #Immunology / Virology & Vaccines #Monoclonal antibodies

How to get your drug to market faster

The pressure to take your drug to market faster is increasing. To achieve a successful journey to the first clinical trial phase in the fastest time possible, Eppendorf has identified three key elements that it is addressing in an eBook.  Comply with audit requirements and relevant certifications  Drive process efficiencies… Read More

#Editor's Choice #News